New-onset diabetes after transplantation

Area of Science:

• Transplantation Medicine
• Endocrinology
• Cardiology

Background:

• New-onset diabetes after transplantation (NODAT) is an underestimated complication of solid-organ transplantation.
• The incidence of NODAT in heart transplant recipients can reach 32% at 5 years, comparable to kidney and liver recipients.
• Risk factors include age, ethnicity, family history, obesity, and immunosuppressants, with corticosteroids posing the highest risk.

Purpose of the Study:

• To highlight the significance of NODAT in solid-organ transplant recipients.
• To review risk factors and potential long-term consequences, including cardiac allograft vasculopathy (CAV).
• To emphasize the importance of the International Consensus Guidelines for managing NODAT.

Main Methods:

• Review of existing studies on NODAT incidence and risk factors in transplant populations.
• Analysis of the impact of immunosuppressive agents, particularly corticosteroids and calcineurin inhibitors (tacrolimus vs. cyclosporine).
• Examination of the relationship between NODAT and post-transplant cardiovascular disease, specifically CAV in heart transplant recipients.

Main Results:

• Heart transplant recipients have a significant cumulative incidence of NODAT.
• Corticosteroids are strongly associated with NODAT; tacrolimus may be more diabetogenic than cyclosporine.
• NODAT is a potential risk factor for CAV, a major cause of mortality in heart transplant patients.

Conclusions:

• NODAT is a critical complication requiring proactive management in transplant recipients.
• International Consensus Guidelines provide a framework for defining, identifying, and managing NODAT.
• Individualized therapeutic strategies based on risk assessment are essential to mitigate NODAT and its adverse outcomes, particularly CAV.